Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01125891 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
A Phase 1 study of Solid Tumors and Malignant Neoplasmas, sponsored by Traws Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT01125891 is a Phase 1 study of Solid Tumors and Malignant Neoplasmas that has completed, run by Traws Pharma. The registered enrollment target is 39 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01125891, a Phase 1 study of Solid Tumors and Malignant Neoplasmas, has completed, sponsored by Traws Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
Treatment of cancer is often more effective when two or more drugs are used together. For example, when gemcitabine, an approved drug, and ON 01910.Na, a new investigational anti-cancer drug, are used together to treat cancer cells in laboratory animals, there is more inhibition of the growth of the cancer cells compared to either drug used by itself. These results offer promise that gemcitabine and ON 01910.Na could be used to treat cancer in patients. However, before studies that seek to find out if gemcitabine and ON 01910.Na is an effective combination in patients can be done, doctors must first know what is largest, safe dose of ON 01910.Na that can be used in combination with gemcitabine. This study is designed to answer that question.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG ON 01910.Na
Study Locations (2)
Colorado
- University of Colorado Cancer Center - Denver
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01125891
The ClinicalTrials.gov registry entry for NCT01125891 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (86% lower). The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.
NCT01125891 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT01125891 about?
NCT01125891 is a clinical study titled "Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors". Treatment of cancer is often more effective when two or more drugs are used together. For example, when gemcitabine, an approved drug, and ON 01910.Na, a new investigational anti-cancer drug, are used together to treat cancer cells in laboratory animals, there is more inhibition of the growth of the...
What is the current status of trial NCT01125891?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2009-01. Estimated completion is 2011-09.
What conditions does trial NCT01125891 study?
This clinical trial studies the following conditions: Solid Tumors, Malignant Neoplasmas.
What interventions are being tested in trial NCT01125891?
The interventions under investigation include: gemcitabine (DRUG), ON 01910.Na (DRUG).
Who is sponsoring clinical trial NCT01125891?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01125891 being conducted?
This trial has 2 study locations across Colorado, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.